LY2062430 (Alzheimer’s disease) – Analysis and Forecasts to 2022

Published by: GlobalData

Published: Apr. 30, 2012 - 35 Pages

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Alzheimer’s Disease

2.2 Symptoms

2.3 Alzheimer’s disease Market

2.4 Epidemiology

2.5 Etiology

2.5.1 Age

2.5.2 Family History

2.5.3 Genetics

2.6 Economic Impact of Alzheimer’s disease

2.7 GlobalData Report Guidance

3 Alzheimer’s disease: Market Characterization

3.1 Alzheimer’s disease Market

3.2 Alzheimer’s disease Market Forecasts and CAGR

3.3 Drivers and Barriers of Alzheimer’s Disease Therapeutics Market

3.3.1 Ageing Population

3.3.2 Patent Expiries

3.3.3 New Product Launches

3.3.4 High Unmet Need

4 Classification of Alzheimer’s disease

4.1 Stage 1 (Mild)

4.2 Stage 2 (Moderate)

4.3 Stage 3 (Severe)

5 Treatment for Alzheimer’s disease

5.1 Cognitive Symptoms

5.1.1 Cholinesterase Inhibitors (ChEIs)

5.1.2 NMDA antagonists

5.1.3 Other Pharmacotherapeutic Agents

5.2 Behavioural Symptoms and Mood Disorders

5.2.1 Non-pharmacological Approaches

5.2.2 Prescription Medicines

5.3 Next-generation Drugs

5.3.1 Disease Modifying Agents

5.3.2 Tau-directed Therapies

5.3.3 Other Therapies

6 LY2062430 (solanezumab)

6.1 Introduction

6.2 Mechanism of Action

6.3 Clinical Studies

6.4 Factors Affecting Sales of LY2062430

6.4.1 Satisfying Unmet Need

6.4.2 Uncertainty over the Approval

6.4.3 Affordability

6.4.4 Low Dosing Convenience

6.5 Drug Evaluation

6.5.1 Drug Risk Benefit Score

6.5.2 Intensity of Competition

6.6 Sales Estimates

6.6.1 Target Patient Pool for LY2062430

6.6.2 Dosing

6.6.3 Market Penetration

6.6.4 Annual Cost of Therapy

6.6.5 Global Sales Projections of LY2062430

7 Alzheimer’s Disease Market: Appendix

7.1 Market Definitions

7.2 List of Abberiviations

7.3 Research Methodology

7.3.1 Coverage

7.3.2 Secondary Research

7.3.3 Forecasting

7.3.4 Number of Patients Approved to Take the Drug

7.3.5 Net Penetration of Drug

7.3.6 Net Annual Dosing

7.3.7 Annual Cost of Therapy

7.4 Drug Sales Estimates Model

7.5 Contact Us

7.6 Disclaimer

7.7 Sources

1.1 List of Tables

Table 1: Alzheimer’s disease, World, Major Pipeline Products in Phase III

Table 2: Mild Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms

Table 3: Moderate Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms

Table 4: Severe Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms

Table 5: Non-pharmacological Approaches for Behavioural Symptoms and Mood Disorders

Table 6: Experimental Disease Modifying Drugs in Phase III for Alzheimer’s disease

Table 7: Drug Risk Benefit Score of LY2062430

Table 8: LY2062430, Alzheimer’s disease , Global, Sales Forecasts ($m), 2013–2022

Table 9: LY2062430, Alzheimer’s disease , The US, Sales Forecasts ($m), 2013–2022

Table 10: LY2062430, Alzheimer’s disease , UK, Sales Forecasts ($m), 2013–2022

Table 11: LY2062430, Alzheimer’s disease, France, Sales Forecasts ($m), 2013–2022

Table 12: LY2062430, Alzheimer’s disease, Germany, Sales Forecasts ($m), 2013–2022

Table 13: LY2062430, Alzheimer’s disease, Italy, Sales Forecasts ($m), 2013–2022

Table 14: LY2062430, Alzheimer’s disease, Spain, Sales Forecasts ($m), 2013–2022

Table 15: LY2062430, Alzheimer’s disease, Japan, Sales Forecasts ($m), 2013–2022

1.2 List of Figures

Figure 1: Brain Affected by Alzheimer’s disease

Figure 2: Estimated Lifetime Risks for Alzheimer’s by Age and Sex, The US

Figure 3: Estimated Number of Cases of Alzheimer’s Disease (million), The US

Figure 4: Changes in Selected Causes of Death, The US, 2000-2008

Figure 5: Alzheimer’s disease, Global, Market Size Forecasts ($bn), 2011–2022

Figure 6: Drug Model Diagram of LY2062430

Figure 7: LY2062430, Alzheimer’s disease, Global, Sales Forecasts ($m), 2013–2022

Figure 8: LY2062430, Alzheimer’s disease, The US, Sales Forecasts ($m), 2013–2022

Figure 9: LY2062430, Alzheimer’s disease, UK, Sales Forecasts ($m), 2013–2022

Figure 10: LY2062430, Alzheimer’s disease, France, Sales Forecasts ($m), 2013–2022

Figure 11: LY2062430, Alzheimer’s disease, Germany, Sales Forecasts ($m), 2013–2022

Figure 12: LY2062430, Alzheimer’s disease, Italy, Sales Forecasts ($m), 2013–2022

Figure 13: LY2062430, Alzheimer’s disease, Spain, Sales Forecasts ($m), 2013–2022

Figure 14: LY2062430, Alzheimer’s disease, Japan, Sales Forecasts ($m), 2013–2022

Figure 15: LY2062430, Global, Sales Distribution, 2022

Figure 16: Patients Approved for the Drug

Abstract

• Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
• Analysis and review of LY2062430 including sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of LY2062430 including efficacy, safety, pricing, competition and other details which influence its sales potential
• Global sales forecast for 2013-2022 for LY2062430

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.